OncoPharma Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Doutor Plácido da Costa, 4200-450 Porto, Portugal.
CINTESIS@RISE, Faculty of Medicine, University of Porto, Alameda Professor Hernâni Monteiro, 4200-319 Porto, Portugal.
Biomolecules. 2022 Jul 26;12(8):1031. doi: 10.3390/biom12081031.
Dostarlimab (JEMPERLI) is a PD-1 monoclonal antibody for the treatment of adult patients, with mismatch repair deficient (dMMR), recurrent or advanced endometrial cancer that has progressed on or following prior therapy with a platinum-containing regimen. As determined by an FDA-approved test this indication was granted rapid approval based on the rate of tumor response and the duration of the response. Continued approval for this indication is conditioned on further confirmatory trials demonstrating and documenting clinical benefit. In June 2022, the clinical trial NCT04165772 reported a 100% remission rate for rectal cancer. This clinical trial brought proof that we can match a tumor and the genetics of what is driving it, with therapy. This clinical trial continues to enroll patient and is currently enrolling patients with gastric, prostate, and pancreatic cancers. Dostarlamib is being recommended for rectal cancer. The focus of this review is to summarize the existing knowledge regarding Dostarlimab and explore the possibilities of mono- and combination therapies.
多塔利单抗（JEMPERLI）是一种 PD-1 单克隆抗体，用于治疗成人错配修复缺陷（dMMR）、复发或晚期子宫内膜癌，这些患者在先前含铂化疗方案治疗后或治疗期间疾病进展。该适应证是基于肿瘤缓解率和缓解持续时间，通过 FDA 批准的检测方法快速批准的。继续批准该适应证取决于进一步的确认性试验，这些试验证明并记录了临床获益。2022 年 6 月，临床试验 NCT04165772 报告了直肠癌的 100%缓解率。该临床试验提供了证据，证明我们可以将肿瘤及其驱动基因与治疗相匹配。该临床试验仍在招募患者，目前正在招募胃癌、前列腺癌和胰腺癌患者。多塔利单抗被推荐用于直肠癌。本综述的重点是总结关于多塔利单抗的现有知识，并探讨单药和联合治疗的可能性。
